Lee et al., 2016 - Google Patents
Novel strategy for a bispecific antibody: induction of dual target internalization and degradationLee et al., 2016
- Document ID
- 9383334280537150932
- Author
- Lee J
- Lee S
- Hwang J
- Oh S
- Kim B
- Jung S
- Shim S
- Lin P
- Lee S
- Cho M
- Koh Y
- Kim S
- Ahn S
- Lee J
- Kim K
- Cheong K
- Choi J
- Kim K
- Publication year
- Publication venue
- Oncogene
External Links
Snippet
Activation of the extensive cross-talk among the receptor tyrosine kinases (RTKs), particularly ErbB family-Met cross-talk, has emerged as a likely source of drug resistance. Notwithstanding brilliant successes were attained while using small-molecule inhibitors or …
- 238000006731 degradation reaction 0 title abstract description 58
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Novel strategy for a bispecific antibody: induction of dual target internalization and degradation | |
| Wilson et al. | Oncogenic functions and therapeutic targeting of EphA2 in cancer | |
| Coleman et al. | Antibody-drug conjugates in lung cancer: dawn of a new era? | |
| Ye et al. | An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies | |
| Boshuizen et al. | Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors | |
| Shin et al. | Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration | |
| Marangoni et al. | CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts | |
| McDonagh et al. | Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3 | |
| Singh et al. | HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development | |
| Hu et al. | Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk | |
| Gao et al. | Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis | |
| Park et al. | Therapeutic targeting of tetraspanin8 in epithelial ovarian cancer invasion and metastasis | |
| Burtness et al. | Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition | |
| Cao et al. | Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity | |
| Masiero et al. | Development of therapeutic anti-JAGGED1 antibodies for cancer therapy | |
| Willuda et al. | Preclinical antitumor efficacy of BAY 1129980—a novel auristatin-based anti-C4. 4A (LYPD3) antibody–drug conjugate for the treatment of non–small cell lung cancer | |
| Pileri et al. | FAT1: a potential target for monoclonal antibody therapy in colon cancer | |
| Meulendijks et al. | Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity | |
| Vigna et al. | Targeting the oncogenic Met receptor by antibodies and gene therapy | |
| Fu et al. | EGFR/Notch antagonists enhance the response to inhibitors of the PI3K-Akt pathway by decreasing tumor-initiating cell frequency | |
| Tao et al. | Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma | |
| Yamamoto et al. | Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors | |
| Yang et al. | Potent anti-angiogenesis and anti-tumor activity of a novel human anti-VEGF antibody, MIL60 | |
| Yang et al. | Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency | |
| Merlino et al. | MEN1309/OBT076, a first-in-class antibody–drug conjugate targeting CD205 in solid tumors |